Adaptyx Biosciences Showcases Breakthrough First-in-Human Continuous Free Cortisol Monitoring at ADA, Revealing Real-Time Hormonal Dynamics Linked to Metabolic, Cardiovascular, Stress, and Sleep Health Adaptyx Biosciences, a Stanford University spinout commercializing more than 18 years of continuous molecular biosensing research, presented…
Tidepool Showcases New Real-World Clinical Data and Landmark Women’s Health Initiative at ADA 2026 Tidepool, the nonprofit leader advancing innovation in diabetes technology, today unveiled new clinical insights and research initiatives in conjunction with the American Diabetes Association’s (ADA) 86th…
OrsoBio to Present Preclinical and Clinical Data from its Mitochondrial Protonophore Portfolio at the American Diabetes Association’s 2026 Scientific Sessions OrsoBio, Inc. a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced new clinical and preclinical data…
CicadaBio Announces Oral Presentation on CC-18, a First-in-Class GLP-1/ActRII Fusion Protein Designed for Muscle-Preservation Weight Loss, at ADA 2026 CicadaBio announced that new preclinical data for CC-18, its investigational GLP-1/anti-ActRII dual-pathway fusion protein, were shared during an oral presentation at…
Beyond Anti-Aging: AV Laboratories Puts Amino Acids at the Forefront of Science-Led Skin Longevity At the AVL Molecular Research Center at the University of Colorado Boulder, AV Laboratories has been studying skin cells to better understand what supports the visible…
Azafaros Announces Publication of Phase 2 RAINBOW Study Data for Nizubaglustat in Molecular Genetics and Metabolism Journal Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, announced the…
Stock Sale Powers Goldenrod into Clinic with 11h program Targeting Brain Inflammation Goldenrod Therapeutics, Inc., an innovator in brain inflammation treatments for multiple neurological conditions, announced that it has completed the initial closing under its $6.5 million Series Seed preferred…
Gilead Sciences and Lakefront Complete Acquisition of Ouro Medicines to Further Expand Inflammation Pipeline Gilead Sciences, Inc. and Lakefront Biotherapeutics NV announced the successful completion of the previously announced acquisition of Ouro Medicines to advance T cell engager therapies for autoimmune diseases.…
Mevion Announces First Clinical Treatment on the MEVION S250-FIT™ Proton Therapy System Mevion Medical Systems, a global leader in compact proton therapy, announced that the world’s first clinical proton therapy treatment delivered inside an existing conventional radiation therapy vault has…
Sasol Advances Strategic Growth in Advanced Materials and Specialty Chemicals with €60 Million Brunsbüttel Investment Sasol International Chemicals announced a €60 million investment at its Brunsbüttel site to expand its advanced materials and specialty chemicals capabilities, reinforcing the company’s position…
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced that the first patient has been dosed…
CitroTech Expands Patent Portfolio, Leading the Market for GPS-Verified, AI-Enabled Deployment of Eco-Friendly Fire Retardants CitroTech announced the continued expansion of its intellectual property (IP) portfolio, reinforcing its position as the only company in wildfire prevention whose platform combines GPS-enabled…